Cabaletta Bio (CABA) to Post Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Cabaletta Bio to post earnings of ($0.37) per share and revenue of $1.6670 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Thursday, May 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. On average, analysts expect Cabaletta Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cabaletta Bio Trading Up 2.0%

Shares of CABA stock traded up $0.06 during mid-day trading on Tuesday, reaching $2.75. The stock had a trading volume of 380,018 shares, compared to its average volume of 3,686,169. The firm has a market capitalization of $447.57 million, a PE ratio of -1.41 and a beta of 3.30. The stock’s 50-day moving average price is $3.04 and its two-hundred day moving average price is $3.04. Cabaletta Bio has a 52-week low of $1.26 and a 52-week high of $4.23.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CABA shares. Wells Fargo & Company raised their target price on Cabaletta Bio from $2.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Friday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of Cabaletta Bio in a report on Monday, May 4th. Jefferies Financial Group reiterated a “buy” rating on shares of Cabaletta Bio in a research report on Wednesday, June 3rd. Wall Street Zen cut Cabaletta Bio from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cabaletta Bio has an average rating of “Moderate Buy” and an average price target of $15.50.

Institutional Trading of Cabaletta Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its position in shares of Cabaletta Bio by 357.1% in the 1st quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock worth $85,000 after acquiring an additional 48,181 shares in the last quarter. Comerica Bank boosted its position in shares of Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after purchasing an additional 39,860 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Cabaletta Bio in the first quarter worth $102,000. XTX Topco Ltd purchased a new stake in Cabaletta Bio in the second quarter worth $148,000. Finally, Marshall Wace LLP raised its holdings in Cabaletta Bio by 470.7% in the second quarter. Marshall Wace LLP now owns 190,957 shares of the company’s stock worth $290,000 after purchasing an additional 157,497 shares in the last quarter.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.